GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
Boeing Experiences Quarterly Revenue Drop Amid Production Challenges, Beat Expectations 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
How marketing classes can rescue ‘ugly produce’ from becoming food waste 
Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Ferrari F1 Announces Multi-Year Partnership with HP as Title Sponsor 
Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
LATAM Airlines Abandons Plans to Acquire Boeing B737 Planes Amid Gol Bankruptcy 
Mercedes-Benz to Release Luxury Electric Van in China 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Visa's Q2 Earnings Surpass Expectations, Fueled by Consumer Spending 
Tesla Nears FSD Licensing Deal with Major Automaker, Hits 1.3 Billion Milestone 
TikTok Vows to Fight US Ban After Biden Signed Bill 
CAMBRIDGE, Mass., Sept. 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 9:55 a.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
